Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol
Open Access
- 30 November 2023
- journal article
- research article
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 30 (6) , 573-583
Abstract
Introduction Despite significant improvement in secondary CardioVascular (CV) preventive strategies, some acute and chronic coronary syndrome (ACS and CCS) patients will suffer recurrent events (also called “extreme CV risk”). Recently new biochemical markers, such as uric acid (UA), lipoprotein A [Lp(a)] and several markers of inflammation, have been described to be associated with CV events recurrence. The SEcondary preVention and Extreme cardiovascular Risk Evaluation (SEVERE-1) study will accurately characterize extreme CV risk patients enrolled in cardiac rehabilitation (CR) programs. Aim. Our aims will be to describe the prevalence of extreme CV risk and its association with newly described biochemical CV risk factors. Aim Our aims will be to describe the prevalence of extreme CV risk and its association with newly described biochemical CV risk factors. Methods We will prospectively enrol 730 ACS/CCS patients at the beginning of a CR program. Extreme CV risk will be retrospectively defined as the presence of a previous (within 2 years) CV events in the patients’ clinical history. UA, Lp(a) and inflammatory markers (interleukin-6 and -18, tumor necrosis factor alpha, C-reactive protein, calprotectin and osteoprotegerin) will be assessed in ACS/CCS patients with extreme CV risk and compared with those without extreme CV risk but also with two control groups: 1180 hypertensives and 765 healthy subjects. The association between these biomarkers and extreme CV risk will be assessed with a multivariable model and two scoring systems will be created for an accurate identification of extreme CV risk patients. The first one will use only clinical variables while the second one will introduce the biochemical markers. Finally, by exome sequencing we will both evaluate polygenic risk score ability to predict recurrent events and perform mendellian randomization analysis on CV biomarkers. Conclusions Our study proposal was granted by the European Union PNRR M6/C2 call. With this study we will give definitive data on extreme CV risk prevalence rising attention on this condition and leading cardiologist to do a better diagnosis and to carry out a more intensive treatment optimization that will finally leads to a reduction of future ACS recurrence. This will be even more important for cardiologists working in CR that is a very important place for CV risk definition and therapies refinement.Keywords
Funding Information
- Dipartimenti di Eccellenza (Italian MUR Dipartimenti di Eccellenza 2023-2027 project (I. 232/2016, art. 1, commi 314 - 337))
- Directorate-General for Research and Innovation (European Union -Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS)
- A. De Gasperis Cardiology and Cardiac Surgery Foundation
This publication has 91 references indexed in Scilit:
- Large-scale association analysis identifies new risk loci for coronary artery diseaseNature Genetics, 2012
- Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromesHeart, 2012
- High Myeloid-Related ProteinStroke, 2010
- Predictors of Cardiac Rehabilitation Referral in Coronary Artery Disease PatientsJACC, 2009
- Hyperuricemia and risk of stroke: A systematic review and meta‐analysisArthritis Care & Research, 2009
- Uric Acid and Cardiovascular RiskNew England Journal of Medicine, 2008
- Associations of Proinflammatory Cytokines With the Risk of Recurrent StrokeStroke, 2008
- Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trialAmerican Heart Journal, 2008
- ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial InfarctionJACC, 2006
- Pentanucleotide TTTTA Repeat Polymorphism of Apolipoprotein(a) Gene and Plasma Lipoprotein(a) Are Associated With Ischemic and Hemorrhagic Stroke in ChineseStroke, 2003